An Open, Single-arm Clinical Study of Envafolimab, Lenvatinib Combined With VP-16 in the Treatment of Platinum-resistant Recurrent Epithelial Ovarian Cancer Primary Fallopian Tube Cancer and Primary Peritoneal Carcinoma
Latest Information Update: 06 Jun 2024
At a glance
- Drugs Envafolimab (Primary) ; Etoposide (Primary) ; Lenvatinib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
Most Recent Events
- 04 Jun 2024 Status changed from not yet recruiting to recruiting.
- 04 Jun 2024 Results ( At the data cutoff date (Nov 30, 2023, n=12)presented at the 60th Annual Meeting of the American Society of Clinical Oncology
- 22 Jun 2022 New trial record